Article
Oncology
Reem D. Mahmood, Danielle Shaw, Tine Descamps, Cong Zhou, Robert D. Morgan, Saifee Mullamitha, Mark Saunders, Nerissa Mescallado, Alison Backen, Karen Morris, Ross A. Little, Susan Cheung, Yvonne Watson, James P. B. O'Connor, Alan Jackson, Geoff J. M. Parker, Caroline Dive, Gordon C. Jayson
Summary: Metastatic colorectal cancer patients receiving standard chemotherapy show changes in cell- and protein-based biomarkers, with no association to survival outcomes. However, an increase in the MRI imaging biomarker K-trans is associated with worse overall survival, indicating potential for directing molecularly targeted therapies.
Article
Pharmacology & Pharmacy
Calin Cainap, Ovidiu-Vasile Bochis, Catalin Vlad, Raluca Popita, Patriciu Achimas-Cadariu, Andrei Havasi, Andreea Vidrean, Alexandra Dranca, Andra Piciu, Anne-Marie Constantin, Tiberiu Tat, Maniu Dana, Ovidiu Crisan, Cosmin Vasile Cioban, Ovidiu Balacescu, Ovidiu Coza, Loredana Balacescu, Monica Mihaela Marta, Madalina Bota, Simona Cainap
Summary: This study examined the use of bevacizumab beyond disease progression in mCRC patients, showing that doubling the dose of bevacizumab may improve survival. Factors such as dose intensity, primary tumor location, and cumulative exposure to bevacizumab beyond progression were found to significantly influence patient survival.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, General & Internal
Niharika B. Mettu, Fang-Shu Ou, Tyler J. Zemla, Thorvardur R. Halfdanarson, Heinz-Josef Lenz, Rimini A. Breakstone, Patrick M. Boland, Oxana Crysler, Christina Wu, Andrew B. Nixon, Emily Bolch, Donna Niedzwiecki, Alicia Elsing, Herbert Hurwitz, Marwan G. Fakih, Tanios Bekaii-Saab
Summary: Cotargeting vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 may produce anticancer activity in refractory metastatic colorectal cancer (mCRC). This study aimed to evaluate the improvement of progression-free survival (PFS) by adding atezolizumab in patients with refractory mCRC and to explore the efficacy in patients with microsatellite-stable (MSS) disease and liver metastasis. The results showed limited clinical benefit of adding atezolizumab to capecitabine and bevacizumab therapy. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more from the dual inhibition of the vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 pathways.
Review
Oncology
Xuelei Chu, Peng Xue, Shijie Zhu
Summary: Chemotherapy dose intensity is a significant parameter in antitumor clinical medication, affecting treatment efficacy, disease prognosis, and patient safety.
Editorial Material
Medicine, General & Internal
Oladapo O. Yeku, Dan L. Longo
Summary: This editorial discusses the scientific basis of a clinical trial conducted by Prager and colleagues, which tested the efficacy of trifluridine-tipiracil and bevacizumab in treating patients with refractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Tomoyuki Nagaoka, Hiroki Osumi, Teruko Ueno, Akira Ooki, Takeru Wakatsuki, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kiyoshi Matsueda, Kensei Yamaguchi, Eiji Shinozaki
Summary: This study evaluated the usefulness of morphologic response (MR) as a factor associated with the therapeutic effects of chemotherapy plus bevacizumab for initially unresectable colorectal liver metastases (CLM). The results showed that MR does not predict the efficacy of chemotherapy plus bevacizumab, but it may be useful when combined with the Response Evaluation Criteria in Solid Tumors (RECIST).
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Zaoqu Liu, Long Liu, Siyuan Weng, Chunguang Guo, Qin Dang, Hui Xu, Libo Wang, Taoyuan Lu, Yuyuan Zhang, Zhenqiang Sun, Xinwei Han
Summary: The study developed a machine learning-based method to predict prognosis, recurrence, and treatment benefits in colorectal cancer patients, and constructed an immune-related long non-coding RNA signature.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Daisuke Kotani, Takayuki Yoshino, Masahito Kotaka, Akihito Kawazoe, Toshiki Masuishi, Hiroya Taniguchi, Kentaro Yamazaki, Takeharu Yamanaka, Eiji Oki, Kei Muro, Yoshito Komatsu, Hideaki Bando, Hironaga Satake, Takeshi Kato, Akihito Tsuji
Summary: The QUATTRO-II study evaluated the safety and efficacy of CAPOXIRI plus bevacizumab compared to FOLFOXIRI plus bevacizumab in mCRC patients, with the recommended doses determined as 200, 130, and 1600 mg/m(2) for irinotecan, oxaliplatin, and capecitabine, respectively, and 7.5 mg/kg for bevacizumab. The study is still ongoing in the randomized portion.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Helene Bellio, Aurelie Bertaut, Alice Hervieu, Sylvie Zanetta, Audrey Hennequin, Julie Vincent, Remi Palmier, Leila Bengrine-Lefevre, Francois Ghiringhelli, Jean-David Fumet
Summary: The treatment of metastatic colorectal cancer involves combination therapies based on various drugs and targeted therapy, with the aim of evaluating safety, tolerance, and efficacy in chemorefractory patients. The study assessed a new regimen, FOLFIRINOX-3 bevacizumab, and found it to be well-tolerated with a high response rate in chemorefractory patients.
Article
Oncology
Feng Wang, Ming -Ming He, Jian Xiao, Yan-Qiao Zhang, Xiang-Lin Yuan, Wei-Jia Fang, Yan Zhang, Wei Wang, Xiao-Hua Hu, Zhi-Gang Ma, Yi-Chen Yao, Zhi-Xiang Zhuang, Fu-Xiang Zhou, Jie-Er Ying, Ying Yuan, Qing-Feng Zou, Zeng-Qing Guo, Xiang-Yuan Wu, Ying Jin, Zong-Jiong Mai, Zhi-Qiang Wang, Hong Qiu, Ying Guo, Si -Mei Shi, Shuang-Zhen Chen, Hui-Yan Luo, Dong-Sheng Zhang, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu
Summary: High-dose vitamin C plus chemotherapy did not show superior progression-free survival compared to chemotherapy alone in patients with metastatic colorectal cancer as first-line treatment, but may be beneficial in patients with mCRC harboring RAS mutation.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Satoshi Fukuda, Yusuke Niisato, Miki Tsuji, Soma Fukuda, Yuya Hagiwara, Tsubasa Onoda, Hirosumi Suzuki, Yoshitaka Tange, Takeshi Yamada, Yoshiyuki Yamamoto, Toshikazu Moriwaki
Summary: This study investigated the association between cumulative bevacizumab dose (CBD) and adverse events in metastatic colorectal cancer (mCRC) patients who received long-term treatment. The results showed that the occurrence and worsening of proteinuria and thromboembolic events markedly increased when the bevacizumab dose exceeded a certain threshold.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Thomas J. George, Alison M. Ivey, Azka Ali, Ji-Hyun Lee, Yu Wang, Karen C. Daily, Brian H. Ramnaraign, Sanda A. Tan, Krista P. Terracina, Thomas E. Read, Long H. Dang, Atif Iqbal
Summary: The study investigated the combination therapy of sorafenib and capecitabine in refractory metastatic colorectal cancer, showing a median progression-free survival of 6.2 months with manageable toxicity. This oral doublet therapy warrants further investigation for clinical use in patients with mCRC.
Article
Oncology
Cecile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, Violaine Randrian, Solene Doat, Cindy Neuzillet, Valerie Moulin, Morgane Stouvenot, Gael Roth, Tiffany Darbas, Benjamin Auberger, Tiphaine Godet, Marion Jaffrelot, Aurelien Lambert, Olivier Dubreuil, Cassandre Gluszak, Alice Bernard-Tessier, Anthony Turpin, Lola-Jade Palmieri, Olivier Bouche, Gael Goujon, Thierry Lecomte, David Sefrioui, Christophe Locher, Lucien Grados, Pauline Gignoux, Stephanie Trager, Elise Nassif, Angelique Saint, Pascal Hammel, Cedric Lecaille, Mathilde Bureau, Marine Perrier, Damien Botsen, Vincent Bourgeois, Julien Taieb, Edouard Auclin
Summary: In second-line treatment, for patients with metastatic colorectal cancer, the combination of FOLFIRI and bevacizumab is associated with longer overall survival and progression-free survival compared to the combination of FOLFIRI and aflibercept.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Public, Environmental & Occupational Health
Lisa Guccione, Karla Gough, Allison Drosdowsky, Timothy Price, Nick Pavlakis, David Wyld, David Ransom, Michael Michael, Penelope Schofield
Summary: This study assessed the healthcare experiences, quality of life, and psychosocial needs of patients with Neuroendocrine tumours (NETs) to identify differences between sub-groups and found a need to improve the information provision for NET patients.
PATIENT EDUCATION AND COUNSELING
(2022)
Article
Genetics & Heredity
Reger R. Mikaeel, Joanne P. Young, Yun Li, Nicola K. Poplawski, Eric Smith, Mehgan Horsnell, Wendy Uylaki, Yoko Tomita, Amanda R. Townsend, Jinghua Feng, Arne Zibat, Silke Kaulfuss, Christian Mueller, Goekhan Yigit, Bernd Wollnik, Hamish Scott, Lesley Rawlings, Denae Henry, Cassandra Vakulin, Andrew Dubowsky, Timothy J. Price
Summary: This report presents findings of two individuals with CRC from a single family carrying a likely-pathogenic inherited germline variant in RNF43. The study shows that this variant results in premature termination of protein synthesis, playing a role in colorectal tumorigenesis.
Article
Surgery
Rebecca Mercieca-Bebber, Renee Eggins, Kilian Brown, Val J. Gebski, Kate Brewer, Lenna Lai, Lisa Bailey, Michael J. Solomon, John W. Lumley, Peter Hewett, Andrew D. Clouston, Kate Wilson, Wendy Hague, Julian Hayes, Stephen White, Matt Morgan, R. John Simes, Andrew R. L. Stevenson
Summary: This study aimed to compare the urinary, bowel, and sexual functioning of rectal cancer patients who underwent open or laparoscopic surgery. The results showed that patients who underwent open surgery had fewer symptoms in bowel and sexual functioning. However, it remains difficult to recommend one surgical approach over the other for rectal resection.
Article
Oncology
Chi Kin Law, Andrew R. L. Stevenson, Michael Solomon, Wendy Hague, Kate Wilson, John R. Simes, Rachael L. Morton
Summary: The study compared total healthcare costs of laparoscopic-assisted surgery and open resection for rectal cancer over a 12-month period. Despite initial differences in costs, the average costs were found to be similar at 12 months, allowing clinicians to choose the surgical approach based on clinical need.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Chi Kin Law, Andrew R. L. Stevenson, Michael Solomon, Wendy Hague, Kate Wilson, John R. Simes, Rachael L. Morton
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Sunil Gupta, Mayenaaz Sidhu, Neal Shahidi, Sergei Vosko, Owen McKay, Farzan Fahrtash Bahin, Simmi Zahid, Anthony Whitfield, Karen Byth, Gregor Brown, Eric Yong Tat Lee, Stephen John Williams, Nicholas Graeme Burgess, Michael John Bourke
Summary: This study aimed to assess the use of prophylactic clip closure in preventing clinically significant post-EMR bleeding within the right colon. The results showed that prophylactic clip closure can reduce the risk of clinically significant post-EMR bleeding in the management of large non-pedunculated colorectal polyps of 20 mm or larger in the right colon.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Oncology
Mia Shepherdson, Shalem Leemaqz, Gurmeet Singh, Courtney Ryder, Shahid Ullah, Karla Canuto, Joanne P. Young, Timothy J. Price, Ross A. McKinnon, Stephen J. Pandol, Claire T. Roberts, Savio George Barreto
Summary: This study found a significant decrease in incidence of gastrointestinal adenocarcinomas in individuals aged >50 years over the last 30 years, while younger individuals showed no significant change and even a trend towards an increase. The incidence was lower in Indigenous patients compared to non-Indigenous patients, but Indigenous patients had worse survival rates.
Article
Gastroenterology & Hepatology
Andrew Dean, Sanjeev Gill, Mark McGregor, Vy Broadbridge, Harri A. Jarvelainen, Timothy Price
Summary: This study investigated the safety and activity of CEND-1 in combination with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. The results showed that CEND-1 had an acceptable safety profile and adverse events similar to nab-paclitaxel and gemcitabine.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Oncology
Julien Taieb, Timothy Price, Loick Vidot, Benedicte Chevallier, Lucjan Wyrwicz, Jean-Baptiste Bachet
Summary: The PRECONNECT trial evaluated the safety and efficacy of trifluridine/tipiracil for metastatic colorectal cancer. Patients received treatment for several cycles and the study found that the time to deterioration of performance status increased with duration of treatment. The data provide confidence for the use of trifluridine/tipiracil in routine practice.
Article
Oncology
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist, Andrew J. Martin, Sonia Yip, Yoon-Koo Kang, Yung-Jue Bang, Li-Tzong Chen, Markus Moehler, Tanios Bekaii-Saab, Thierry Alcindor, Christopher J. O'Callaghan, Niall C. Tebbutt, Wendy Hague, Howard Chan, Sun Young Rha, Keun-Wook Lee, Val Gebski, Anthony Jaworski, John Zalcberg, Timothy Price, John Simes, David Goldstein
Summary: This study aims to evaluate the efficacy and safety of regorafenib alone and in combination with nivolumab in advanced gastro-oesophageal cancer patients. The study consists of two international randomized controlled trials, comparing the efficacy of regorafenib versus placebo, and the efficacy of regorafenib plus nivolumab versus chemotherapy. The primary endpoint of the study is overall survival.
Review
Oncology
Tharani Krishnan, Fiona Wang, Chris Karapetis, Amitesh Roy, Timothy Price
Summary: Colorectal cancer is a heterogeneous disease with different subtypes related to the primary site. The primary colon tumor side is both a prognostic factor and a predictive marker in metastatic colorectal cancer. This review examines the evidence for its prognostic and predictive value.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Review
Biochemistry & Molecular Biology
Bimala Dhakal, Yoko Tomita, Paul Drew, Timothy Price, Guy Maddern, Eric Smith, Kevin Fenix
Summary: Cancer metabolic plasticity, particularly fatty acid metabolism, plays a crucial role in cancer cell growth and malignancy. The drug perhexiline, which inhibits mitochondrial enzymes involved in fatty acid metabolism, has shown promising anti-cancer properties both as a monotherapy and in combination with traditional chemotherapeutics. This review explores the mechanisms of perhexiline's anti-cancer activities, including both CPT1/2 dependent and independent pathways, and discusses its potential as an anti-cancer agent, limitations, and ability to reduce cardiotoxicity induced by other chemotherapeutics.
Review
Oncology
Celine Man Ying Li, Yoko Tomita, Bimala Dhakal, Runhao Li, Jun Li, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Kevin Aaron Fenix
Summary: This review systematically assessed the efficacy of cytokine-induced killer cell (CIK) therapy for colorectal cancer (CRC) treatment and found that CIK therapy improved overall survival, progression-free survival, and overall response rate without increasing toxicity. Further investigation into CIK therapy for CRC treatment is warranted.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Lisa Guccione, Karla Gough, Allison Drosdowsky, Timothy Price, Nick Pavlakis, David Wyld, David Ransom, Michael Michael, Penelope Schofield
Summary: This study identifies the healthcare preferences, patient experiences, and quality of life of patients with NETs at a 6-month follow-up. The research findings show that there are suboptimal experiences of care, such as low involvement in decision making and difficulties in accessing and understanding information. The study suggests that addressing these issues can improve patient care and quality of life.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Lucjan Wyrwicz, Julien Taieb, Timothy Price, Jean-Baptise Bachet, Meinolf Karthaus, Loick Vidot, Benedicte Chevallier, Timo Reislaender, Lena Weiss, Volker Heinemann
Summary: This study evaluated the association between Eastern Cooperative Oncology Group performance status (ECOG PS) and QLQ-C30 Global Health Status (GHS) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) treatment. The results showed that there was no clinically relevant change in QLQ-C30 GHS score through cycle 7 and 63.0% of patients maintained/improved ECOG PS. The presence of liver metastasis increased the risk of QLQ-C30 GHS score/ECOG PS deterioration.